產(chǎn)品詳情
簡(jiǎn)單介紹：
Anti-PLAC8抗體產(chǎn)品質(zhì)量穩(wěn)定，實(shí)驗(yàn)效果明顯，貨期快，價(jià)格優(yōu)惠，歡迎垂詢訂購(gòu)！我公司長(zhǎng)期供應(yīng)**組化抗體、WB抗體、**組化試劑盒和抗體試驗(yàn)所需全部相關(guān)試劑、熒光標(biāo)記抗體、單克隆抗體、多克隆抗體、各種標(biāo)記的二抗IgG/IgM/IgD/IgA等科研實(shí)驗(yàn)抗體。Anti-PLAC8抗體用于**組化實(shí)驗(yàn),WB實(shí)驗(yàn),相應(yīng)的標(biāo)記抗體有HRP標(biāo)記抗體,FITC標(biāo)記,BIO等。
詳情介紹：
Rabbit Anti-PLAC8
Cat. Number:
Anti-PLAC8抗體KL-15584R
Quantity size:
0.2ml
Concentration:
1mg/ml Buffer = 0.01M TBS(pH7.4) with 1% BSA, 0.03% Proclin300 and 50% Glycerol.
Background:
PLAC8 is a 115 amino acid protein belonging to the cornifelin family that is expressed at high levels in plasmacytoid dendritic Anti-PLAC8抗體cells and other organs of the immune system including lymph nodes, spleen, bone marrow and peripheral blood leukocytes, with lower expression in appendix, thymus and fetal liver. Human PLAC8 shares 83% homology with murine PLAC8, where it has been identified in placenta from 9.5-18.5 days postcoitum. The gene encoding PLAC8 maps to human chromosome 4, which represents approximately 6% of the human genome and contains nearly 900 genes. Notably, the Huntingtin gene, which is found to encode an expanded glutamine tract in cases of Huntington's disease, is on chromosome 4. FGFR-3 is also encoded on chromosome 4 and has been associated with thanatophoric dwarfism, achondroplasia, Muenke syndrome and bladder cancer. Chromosome 4 is also tied to Ellis-van Creveld syndrome, methylmalonic acidemia and polycystic kidney disease
Also known as:
C15; Onzin; PLAC8; PLAC8_HUMAN;Anti-PLAC8抗體 Placenta specific 8; Placenta-specific gene 8 protein; Protein C15.
Specificity:
●
Rabbit Polyclonal IgG, affinity purified by Protein A.
●
Reacts with: Human, Mouse, Rat, Anti-PLAC8抗體Chicken, Dog, Cow, Horse, Rabbit, Sheep, .
●
Immunogen: KLH conjugated synthetic peptide derived from human PLAC8 .
●
Predicted Molecular Weight: 13kDa.
Storage:
Shipped at 4℃, Store at -20℃ (Avoid repeated freeze/thaw cycles).
Application:
WB=1:100-500 ELISA=1:500-1000 IHC-P=1:100-500 IHC-F=1:100-500 ICC=1:100-500 IF=1:100-500 Anti-PLAC8抗體
Not yet tested in other applications.
Optimal working dilutions must be determined by the end user.
Not yet tested in other applications.
Optimal working dilutions must be determined by the end user.
